Cathie Wood Dumped These 3 Stocks in July

Page 1 of 3

In this article, we discuss the 3 stocks that Cathie Wood dumped in July. If you want to see more stocks that she disposed of during this month, click Cathie Wood Dumped These 7 Stocks in July

3. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 35

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a Massachusetts-based genome editing company that develops novel genomic medicines using CRISPR/Cas9 technology for the treatment of ocular diseases. On July 14, Cathie Wood’s ARK Innovation ETF sold 60,190 shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA). 

Piper Sandler analyst Swapnil Malekar reiterated an Overweight rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) with a $171 price target after updated data was disclosed from NTLA-2001 in transthyretin amyloidosis with polyneuropathy. This data “continues to increase our conviction in the potential for one time treatment option for NTLA-2001”, the analyst told investors. 

Among the hedge funds tracked by Insider Monkey, Intellia Therapeutics, Inc. (NASDAQ:NTLA) was part of 35 public stock portfolios as of Q1 2022, up from 31 funds in the prior quarter. Andreas Halvorsen’s Viking Global is a prominent stakeholder of the company, with roughly 2.5 million shares worth $179.40 million. 

Carillon Tower Advisers discussed its stance on Intellia Therapeutics, Inc. (NASDAQ:NTLA) in its Q2 2021 investor letter.

“Intellia Therapeutics is a clinical-stage genome editing company focused on the development of proprietary, potentially curative therapeutics. The company’s stock soared after announcing positive interim data from an ongoing phase 1 clinical study of its in vivo gene editing candidate, which is being developed as a single-dose treatment for hereditary transthyretin (ATTR) amyloidosis. This specific form of therapy would be the first of its kind resulting in the precision editing of a gene in a target tissue in the human body.”

Page 1 of 3